Abstract
Parkinsons disease is a neurodegenerative movement disorder caused by a combination of environmental and genetic factors. Recent human genetic studies have identified five genes that are linked to Parkinsons disease (PD): α-synuclein, parkin, UCH-L1, DJ-1 and NR4A2. Among these genes, a variety of mutations in the human parkin locus have been found in many PD cases, both familial and sporadic. Parkin appears to be the most prevalent genetic factor in PD. It encodes for a protein-ubiquitin E3 ligase, whose loss-offunction mutations cause specific degeneration of dopamine (DA) neurons in substantia nigra in human patients. The accumulation of parkin substrates is thought to be the key factor in the selective death of DA neurons. Rapid progress in the identification of these substrates and the generation of genetic animal models has produced a plethora of knowledge about the biological function of parkin and its role in PD. These studies also offer novel pharmacological targets for the development of more selective therapeutic strategies. In this review, I will summarize results from this fast expanding field and discuss their potential implication in the treatment of Parkinsons disease.
Keywords: parkin, synuclein, parkinson's disease, ubiquitination, misfolding, microtubule, dopamine, tubulin
Current Neuropharmacology
Title: Genetic Factors in Parkinsons Disease and Potential Therapeutic Targets
Volume: 1 Issue: 4
Author(s): Jian Feng
Affiliation:
Keywords: parkin, synuclein, parkinson's disease, ubiquitination, misfolding, microtubule, dopamine, tubulin
Abstract: Parkinsons disease is a neurodegenerative movement disorder caused by a combination of environmental and genetic factors. Recent human genetic studies have identified five genes that are linked to Parkinsons disease (PD): α-synuclein, parkin, UCH-L1, DJ-1 and NR4A2. Among these genes, a variety of mutations in the human parkin locus have been found in many PD cases, both familial and sporadic. Parkin appears to be the most prevalent genetic factor in PD. It encodes for a protein-ubiquitin E3 ligase, whose loss-offunction mutations cause specific degeneration of dopamine (DA) neurons in substantia nigra in human patients. The accumulation of parkin substrates is thought to be the key factor in the selective death of DA neurons. Rapid progress in the identification of these substrates and the generation of genetic animal models has produced a plethora of knowledge about the biological function of parkin and its role in PD. These studies also offer novel pharmacological targets for the development of more selective therapeutic strategies. In this review, I will summarize results from this fast expanding field and discuss their potential implication in the treatment of Parkinsons disease.
Export Options
About this article
Cite this article as:
Feng Jian, Genetic Factors in Parkinsons Disease and Potential Therapeutic Targets, Current Neuropharmacology 2003; 1 (4) . https://dx.doi.org/10.2174/1570159033477053
DOI https://dx.doi.org/10.2174/1570159033477053 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Functional Activity and Connectivity Differences of Five Resting-State Networks in Patients with Alzheimer’s Disease or Mild Cognitive Impairment
Current Alzheimer Research 1,2,4-Triazine Analogs as Novel Class of Therapeutic Agents
Mini-Reviews in Medicinal Chemistry Recent Developments of the PET Imaging Agents for Metabotropic Glutamate Receptor Subtype 5
Current Topics in Medicinal Chemistry Exercise Addiction- Diagnosis, Bio-Psychological Mechanisms and Treatment Issues
Current Pharmaceutical Design The Pathophysiology of Tics; An Evolving Story
Current Drug Therapy Consciousness, Functional Networks and Delirium Screening
Current Aging Science Neuroprotection by Estrogen and Progesterone in Traumatic Brain Injury and Spinal Cord Injury
Current Neuropharmacology Adsorption and Bioactivity of Tyrosine Hydroxylase on Gold Surfaces and Nanoparticles
Protein & Peptide Letters How to Measure Exercise Performance
Current Respiratory Medicine Reviews Neurotrophic Factors for the Investigation and Treatment of Movement Disorders
Current Medicinal Chemistry - Central Nervous System Agents Plasma Rich in Growth Factors Enhances Wound Healing and Protects from Photo-oxidative Stress in Dermal Fibroblasts and 3D Skin Models
Current Pharmaceutical Biotechnology Proteinase K-Resistant Aggregates of Recombinant Prion Protein PrP-(23-98) Are Toxic to Cultured Cells
Protein & Peptide Letters Clinical Advances in Bone Regeneration
Current Stem Cell Research & Therapy Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews Hospital Exemption for Advanced Therapy Medicinal Products: Issue in Application in the European Union Member States
Current Stem Cell Research & Therapy An Update on GABAρ Receptors
Current Neuropharmacology Fructose 1,6-Bisphosphate: A Summary of Its Cytoprotective Mechanism
Current Medicinal Chemistry Partial QSAR Analysis of Some Selected Natural Inhibitors of FAAH Suggests a Working Hypothesis for the Development of Endocannabinoid- Based Drugs
Current Drug Targets - CNS & Neurological Disorders Septomics: Application of Systems Approaches to Sepsis - Potential for Personalized Management of Septic Patients
Current Pharmacogenomics and Personalized Medicine Carbon Nano Tubes: Novel Drug Delivery System in Amelioration of Alzheimer’s Disease
Combinatorial Chemistry & High Throughput Screening